Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4971 |
Name | myelofibrosis |
Definition | A myeloid neoplasm that is located in the bone marrow which results in bone marrow being replaced by fibrous (scar) tissue. |
Source | DiseaseOntology.org |
Alt Ids | DOID:5737 |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm myelofibrosis |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
JAK2 V617F | N/A | myelofibrosis | not applicable | detail... |
IDH1 mutant | N/A | myelofibrosis | not applicable | detail... |
IDH2 mutant | N/A | myelofibrosis | not applicable | detail... |
DNMT3A mutant | N/A | myelofibrosis | not applicable | detail... |
CBL mutant | N/A | myelofibrosis | not applicable | detail... |
JAK2 V617F | INCB053914 | myelofibrosis | predicted - sensitive | detail... |
JAK2 mutant | N/A | myelofibrosis | not applicable | detail... |
TET2 mutant | N/A | myelofibrosis | not applicable | detail... |
JAK2 V617F | C220 | myelofibrosis | predicted - sensitive | detail... |
NRAS mutant | N/A | myelofibrosis | not applicable | detail... |
JAK2 V617F | Binimetinib + Ruxolitinib | myelofibrosis | sensitive | detail... |
JAK2 V617F | Flonoltinib maleate | myelofibrosis | sensitive | detail... |
JAK2 V617F | INCB160058 | myelofibrosis | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01398462 | Phase I | CWP232291 | Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | Completed | USA | 1 |
NCT01644110 | Phase Ib/II | Pomalidomide + Ruxolitinib | Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF (POMINC) | Active, not recruiting | DEU | 0 |
NCT01787487 | Phase II | Azacitidine + Ruxolitinib | Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm | Recruiting | USA | 0 |
NCT02098161 | Phase II | LCL161 | LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis | Completed | USA | 0 |
NCT02158858 | Phase Ib/II | CPI-0610 + Ruxolitinib CPI-0610 | A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | DEU | CAN | BEL | 0 |
NCT02251821 | Phase II | Fludarabine Tacrolimus Mycophenolate mofetil Busulfan Pacritinib Momelotinib Melphalan Methotrexate Ruxolitinib Cyclophosphamide | JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis | Active, not recruiting | USA | 0 |
NCT02268253 | Phase II | Tagraxofusp-erzs | Tagraxofusp (SL-401) in Patients With CMML or MF | Completed | USA | CAN | 0 |
NCT02386800 | FDA approved | Ruxolitinib Panobinostat + Ruxolitinib | CINC424A2X01B Rollover Protocol | Active, not recruiting | TUR | SWE | POL | LBN | ITA | ISR | HUN | GRC | FRA | ESP | DEU | CAN | BGR | BEL | AUS | 10 |
NCT02421354 | Phase II | Nivolumab | Study of Nivolumab in Patients With Myelofibrosis | Terminated | USA | 0 |
NCT02440685 | Phase Ib/II | ASN002 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | Terminated | USA | ARG | 0 |
NCT02493530 | Phase I | Ruxolitinib + Umbralisib | TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea | Completed | USA | 0 |
NCT02528877 | Phase I | Fludarabine + Melphalan Ruxolitinib + Sirolimus + Tacrolimus | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis | Withdrawn | USA | 0 |
NCT02530034 | Phase I | Hu8F4 | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT02530619 | Phase I | Alisertib | Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia | Unknown status | USA | 0 |
NCT02564536 | Phase I | Decitabine + Pacritinib | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | Withdrawn | 0 | |
NCT02718300 | Phase II | Parsaclisib + Ruxolitinib | A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | Terminated | USA | 0 |
NCT02966353 | Phase II | Ruxolitinib | Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE) | Completed | TUR | ITA | GRC | ESP | DEU | CAN | BGR | BEL | AUT | 2 |
NCT03042689 | Phase I | Regorafenib | Study of Regorafenib in Patients With Advanced Myeloid Malignancies | Completed | USA | 0 |
NCT03065400 | Phase II | Pembrolizumab | PD-1 Inhibition in Advanced Myeloproliferative Neoplasms | Completed | USA | 0 |
NCT03136185 | Phase II | IMG-7289 | IMG-7289 in Patients With Myelofibrosis | Completed | USA | ITA | GBR | DEU | AUS | 0 |
NCT03144687 | Phase II | Itacitinib + Ruxolitinib Itacitinib | A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis | Completed | USA | NLD | AUT | 0 |
NCT03165734 | Phase II | Lenalidomide Ruxolitinib Hydroxyurea Pacritinib Thalidomide | A Phase 2/3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA) | Recruiting | USA | ROU | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BGR | AUS | 8 |
NCT03289910 | Phase II | Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | Active, not recruiting | USA | 0 |
NCT03326310 | Phase I | Azacitidine + Selumetinib | Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia | Recruiting | USA | 0 |
NCT03373877 | Phase I | PU-H71 + Ruxolitinib | Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis | Terminated | USA | 0 |
NCT03441113 | Phase II | Momelotinib | Extended Access of Momelotinib in Adults With Myelofibrosis | Active, not recruiting | USA | ROU | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BGR | BEL | AUT | AUS | 3 |
NCT03480360 | Phase III | Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | Active, not recruiting | USA | 0 |
NCT03592576 | Expanded access | Navitoclax | Expanded Access to Navitoclax | No longer available | 0 | |
NCT03627403 | Phase II | Selinexor | Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (ESSENTIAL) | Active, not recruiting | USA | 0 |
NCT03645824 | Phase II | Pacritinib | Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) (HOVON134MF) | Active, not recruiting | NLD | BEL | 0 |
NCT03662126 | Phase II | KRT-232 | KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor | Recruiting | USA | TUR | ROU | POL | LTU | ITA | ISR | HUN | HRV | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | AUS | ARG | 8 |
NCT03755518 | Phase III | Fedratinib | An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM) | Completed | USA | CAN | 0 |
NCT03862157 | Phase Ib/II | Azacitidine + MLN4924 + Venetoclax | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03886831 | Phase I | PRT543 | A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies | Completed | USA | 0 |
NCT03895112 | Phase I | BMS-986416 | MPN-RC 118 AVID200 in Myelofibrosis | Completed | USA | 0 |
NCT03912064 | Phase I | Ipilimumab | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT | Active, not recruiting | USA | 0 |
NCT03935555 | Phase I | PU-H71 | Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib | Terminated | USA | 0 |
NCT03952039 | Phase III | Fedratinib | An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2) | Active, not recruiting | POL | NLD | ITA | IRL | HUN | GBR | FRA | ESP | DEU | CZE | BEL | AUT | AUS | 3 |
NCT04041050 | Phase I | Navitoclax Navitoclax + Ruxolitinib | A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | Active, not recruiting | USA | TUR | SWE | ITA | HRV | GBR | FRA | ESP | DEU | BGR | BEL | 3 |
NCT04089449 | Phase I | PRT811 | A Study of PRT811 in Participants With Advanced Solid Tumors, Gliomas and Myelofibrosis | Completed | USA | 0 |
NCT04173494 | Phase III | Danazol Momelotinib | A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM) | Completed | USA | SWE | ROU | POL | NZL | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BGR | BEL | AUT | AUS | 3 |
NCT04176198 | Phase I | TP-3654 | A Study of Oral TP-3654 in Patients With Myelofibrosis | Recruiting | USA | ITA | GBR | FRA | CAN | BEL | AUS | 1 |
NCT04279847 | Phase I | INCB057643 | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (LIMBER) | Recruiting | USA | NLD | ITA | GBR | FIN | ESP | CAN | 1 |
NCT04281498 | Phase II | Enasidenib + Ruxolitinib | Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation | Completed | USA | CAN | 0 |
NCT04282187 | Phase II | Decitabine + Fedratinib Decitabine + Ruxolitinib | Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | Recruiting | USA | 0 |
NCT04454658 | Phase I | ABBV-744 ABBV-744 + Navitoclax ABBV-744 + Ruxolitinib | Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis | Active, not recruiting | USA | TUR | SWE | ITA | ISR | HUN | ESP | BRA | BGR | AUS | ARG | 3 |
NCT04468984 | Phase III | Navitoclax + Ruxolitinib | Safety, Efficacy, and Assessment of Change in Spleen Volume Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2) | Active, not recruiting | USA | TUR | SWE | POL | NZL | ITA | ISR | HUN | HRV | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BGR | BEL | AUT | AUS | 7 |
NCT04472598 | Phase III | Ruxolitinib Navitoclax + Ruxolitinib | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (TRANSFORM-1) | Active, not recruiting | USA | TUR | SWE | NZL | NLD | ITA | ISR | HRV | GRC | GBR | FRA | ESP | DEU | CAN | BGR | BEL | AUT | AUS | 7 |
NCT04480086 | Phase I | Mivebresib + Navitoclax Mivebresib + Ruxolitinib Mivebresib | Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis | Terminated | USA | 2 |
NCT04485260 | Phase Ib/II | KRT-232 + Ruxolitinib | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib | Unknown status | USA | POL | ITA | ISR | FRA | ESP | DEU | BGR | AUS | 0 |
NCT04517851 | Phase I | Elotuzumab | Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis | Active, not recruiting | USA | 0 |
NCT04551053 | Phase III | Parsaclisib + Ruxolitinib Ruxolitinib | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | Terminated | USA | TUR | ROU | POL | NOR | ITA | ISR | HUN | GBR | FRA | FIN | ESP | DEU | BEL | AUT | 4 |
NCT04551066 | Phase III | Ruxolitinib Parsaclisib + Ruxolitinib | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | Active, not recruiting | USA | TUR | POL | NOR | ITA | ISR | GBR | FRA | FIN | ESP | DNK | DEU | BEL | AUT | 3 |
NCT04562389 | Phase III | Ruxolitinib + Selinexor Ruxolitinib | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | Recruiting | USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BGR | BEL | 3 |
NCT04576156 | Phase III | Thalidomide Danazol Hydroxyurea Imetelstat | A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment | Recruiting | USA | TUR | POL | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | BRA | BGR | BEL | AUT | AUS | ARG | 9 |
NCT04603495 | Phase III | CPI-0610 + Ruxolitinib Ruxolitinib | Study of CPI-0610 in Myelofibrosis (MF) (MANIFEST-2) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT | AUS | 5 |
NCT04629508 | Phase II | Itacitinib | To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy. | Completed | USA | POL | ITA | ESP | DEU | BEL | AUT | 0 |
NCT04655118 | Phase II | TL-895 | Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis | Recruiting | USA | POL | ITA | HUN | FRA | ESP | DEU | BRA | BGR | BEL | AUS | 2 |
NCT04676529 | Phase Ib/II | PXS-5505 | Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis | Active, not recruiting | USA | AUS | 2 |
NCT04771572 | Phase I | LP-118 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Recruiting | USA | 0 |
NCT04817007 | Phase I | BMS986158 + Ruxolitinib BMS986158 + CYC065 BMS986158 | A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) | Active, not recruiting | USA | ROU | POL | ITA | ISR | HUN | GRC | FRA | ESP | DEU | AUS | 1 |
NCT04854096 | Phase II | Ilginatinib | Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis | Terminated | USA | TUR | POL | ITA | GBR | DEU | 3 |
NCT04878003 | Phase II | TL-895 KRT-232 | Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naive Myelofibrosis | Recruiting | USA | POL | BGR | 6 |
NCT04896112 | Phase I | LNK01002 | A Study of LNK01002 in Patients With Primary (PMF) or Secondary Myelofibrosis (PV-MF, ET-MF) or Acute Myeloid Leukemia | Withdrawn | USA | 0 |
NCT04955938 | Phase I | Enasidenib + Fedratinib Fedratinib + Ivosidenib | A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | Withdrawn | USA | 0 |
NCT05127174 | Phase Ib/II | Fedratinib | Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms | Active, not recruiting | USA | 0 |
NCT05455294 | Phase I | Decitabine + Navitoclax + Venetoclax | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | Active, not recruiting | USA | 0 |
NCT05467800 | Phase II | Canakinumab | Study of Canakinumab in Patients With Myelofibrosis | Active, not recruiting | USA | 0 |
NCT05714072 | Phase I | Abemaciclib + Ruxolitinib | A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | Recruiting | USA | 0 |
NCT05835466 | Phase II | Reparixin | Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) | Recruiting | USA | 0 |
NCT05936359 | Phase I | INCA033989 INCA033989 + Ruxolitinib | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | Recruiting | ITA | GBR | FRA | ESP | DNK | DEU | CAN | AUS | 1 |
NCT06034002 | Phase I | INCA033989 | A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms | Recruiting | USA | 0 |
NCT06150157 | Phase I | JNJ-88549968 | A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms | Recruiting | USA | GBR | FRA | ESP | DEU | CAN | 0 |
NCT06218628 | Phase I | Pacritinib + Talazoparib | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | Recruiting | USA | 0 |
NCT06291987 | Phase I | Ivosidenib + Ruxolitinib | Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation (MPN) | Recruiting | USA | 0 |
NCT06313593 | Phase I | INCB160058 | A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | Recruiting | USA | 0 |
NCT06327100 | Phase II | Tasquinimod Ruxolitinib + Tasquinimod | Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) | Recruiting | USA | 0 |
NCT06343805 | Phase I | AJ1-11095 | A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) | Recruiting | USA | 0 |